Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11337622 | 0.81 | ADORA3 (0.31) | ADORA3ADORA1ADORA2A | |
| SCHEMBL20464457 | 0.81 | MEN1 (0.33) | ADORA3ADORA1ADORA2A | |
| SCHEMBL2756565 | 0.74 | — | — | |
| SCHEMBL18930207 | 0.73 | — | — | |
| SCHEMBL19622438 | 0.72 | ADORA3 (0.36) | ADORA3ADORA1ADORA2A | |
| SCHEMBL890172 | 0.69 | — | — | |
| SCHEMBL20464463 | 0.68 | TSHR (0.35) | ADORA3ADORA1ADORA2A | |
| SCHEMBL17321274 | 0.67 | AAK1 (0.34) | ADORA3ADORA1ADORA2A | |
| SCHEMBL21375442 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL19228479 | 0.63 | L3MBTL1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023212240-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| US-20230126271-A1 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230058677-A1 | POLYCYCLIC PYRIDOPYRAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| US-9745313-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-29 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| WO-2015125785-A1 | PYRAZOLONE DERIVATIVE HAVING MULTIPLE SUBSTITUENTS | 第一三共株式会社 | 2015-08-27 | — | — | WO | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20100093795-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20080139613-A1 | Chemical Compound | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ADORA3 962/4885ADORA1 1459/4885ADORA2A 1879/4885 |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | ADORA3 2270/4885ADORA1 1414/4885ADORA2A 1741/4885 |
| US-20100093795-A1 | Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases | CCR5, CCL5, CXCR5 | ADORA3 304/4885ADORA1 271/4885ADORA2A 317/4885 |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | ADORA3 2077/4885ADORA1 2860/4885ADORA2A 1563/4885 |
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | ADORA3 489/4885ADORA1 516/4885ADORA2A 224/4885 |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, PLA2G10, LPCAT1 | ADORA3 1843/4885ADORA1 874/4885ADORA2A 789/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ADORA3 4065/4885ADORA1 4344/4885ADORA2A 4182/4885 |
| US-20230030414-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ADORA3 3491/4885ADORA1 3547/4885ADORA2A 2723/4885 |
| US-20230126271-A1 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | PSMA4, PSMB4, PSMB1 | ADORA3 4522/4885ADORA1 4564/4885ADORA2A 4520/4885 |
| US-20080139613-A1 | Chemical Compound | CCR5, CCR2, CCR1 | ADORA3 397/4885ADORA1 329/4885ADORA2A 978/4885 |
| US-20230058677-A1 | POLYCYCLIC PYRIDOPYRAZINE DERIVATIVE | C5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3 | ADORA3 975/4885ADORA1 1422/4885ADORA2A 1623/4885 |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, VIP | ADORA3 2937/4885ADORA1 3808/4885ADORA2A 3735/4885 |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | NR4A3, NR4A1, NR3C1 | ADORA3 1602/4885ADORA1 3119/4885ADORA2A 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.